Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1645 1656 1674
This examiner grants 0% of resolved cases
Syed Jarar Abbas is an examiner in Tech Center 1600 and Art Unit 1618. The data for this profile is limited to 2 resolved cases, both of which resulted in an allowance rate of 0.0 percent. This small sample size makes it difficult to draw broad conclusions about long-term trends.
The median days to allowance is 1196, though this figure is based on the very few cases resolved. Similarly, the interview lift is currently 0.0 percent. Practitioners should monitor this profile as more cases are resolved to see if the 0.0 percent allowance rate changes with a larger dataset.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18516561 | SYNTHETIC IL6-IL1BETA FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18253702 | ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18277576 | INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 17689117 | METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY | Non-Final OA | The General Hospital Corporation |
| 18303421 | IL-17 RECEPTOR MODULATOR SCREENING SYSTEM | Non-Final OA | New York University |
| 18296755 | EXOSOME ENCODED IL-10 AS A TREATMENT FOR INFLAMMATION ASSOCIATED ADVERSE PREGNANCY CONDITION | Final Rejection | Board of Regents, The University of Texas System |
| 19065656 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | Final Rejection | NOVARTIS AG |
| 18706732 | METHODS OF TREATING MITOCHONDRIAL MYOPATHIES USING ANTI-GDF15 ANTIBODIES | Non-Final OA | PFIZER INC. |
| 18262392 | SINGLE DOMAIN ANTIBODIES TARGETING CA-IX AS WELL AS COMPOSITIONS COMPRISING SAME | Non-Final OA | National Research Council of Canada |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18033524 | IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING NON-MELANOMA SKIN CANCER | Non-Final OA | Cytune Pharma |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy